In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diabetes And Oncology Drive Interest in China - Shanghai R&D Summit

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Pharma companies and investors are focusing their interest in China, as they are elsewhere, on diabetes and oncology, but they face unique challenges, according to panelists at a recent R&D conference in Shanghai

You may also be interested in...



China's Drug Regulators Issue Warning On Use Of Avandia While Debating Suspension Vs. Restricted Use

SHANGHAI - China's State FDA issued a warning Sept. 25 on the potential cardiovascular risk of using drugs containing rosiglitazone and told the public that the agency is organizing a committee of experts to evaluate the benefits and risks of rosiglitazone drugs, including GlaxoSmithKline's Avandia (rosiglitazone), Avandamet (metformin and rosiglitazone) and generics

China's Drug Regulators Issue Warning On Use Of Avandia While Debating Suspension Vs. Restricted Use

SHANGHAI - China's State FDA issued a warning Sept. 25 on the potential cardiovascular risk of using drugs containing rosiglitazone and told the public that the agency is organizing a committee of experts to evaluate the benefits and risks of rosiglitazone drugs, including GlaxoSmithKline's Avandia (rosiglitazone), Avandamet (metformin and rosiglitazone) and generics

China's Generic Companies Leaning Toward Innovation To Target Global Market: FT China Healthcare And Life Science Summit

SHANGHAI - While China reported a slowdown of its economic growth in the second quarter - 10.3 percent compared to 11.9 percent in the same year-ago quarter - many economists feared China was close to overheating, but the life science industry in China is still hot to global investors, and Chinese generics companies are evolving to become more integrated and innovative, according to speakers from the FT China Healthcare and Life Science Summit held in Shanghai July 13

Related Content

UsernamePublicRestriction

Register

SC074749

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel